Get the Stockscreener App
10.69
2.31%
-0.11
Benitec Biopharma Inc stock is traded at $10.69, with a volume of 7,641.
It is down -2.31% in the last 24 hours and up +11.29% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$10.80
Open:
$10.7
24h Volume:
7,641
Relative Volume:
0.27
Market Cap:
$213.01M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-0.631
EPS:
-16.9418
Net Cash Flow:
$-18.07M
1W Performance:
-2.59%
1M Performance:
+11.29%
6M Performance:
+17.88%
1Y Performance:
+173.32%
1-Day Range:
$10.55
$10.80
1-Week Range:
$10.30
$10.93
52-Week Range:
$2.69
$12.89
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
Benitec Biopharma Inc Stock (BNTC) Latest News
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference - GlobeNewswire
Long Term Trading Analysis for (BNTC) - Stock Traders Daily
Piper Sandler Initiates Coverage of Benitec Biopharma (BNTC) with Overweight Recommendation - MSN
Janus Henderson Group PLC Expands Investment in Benitec Biopharm - GuruFocus.com
Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $19.50 Average Price Target from Analysts - Defense World
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts (NASDAQ:BNTC) - Seeking Alpha
Q1 Earnings Estimate for BNTC Issued By Leerink Partnrs - MarketBeat
Benitec started at outperform by Oppenheimer on gene therapy potential (NASDAQ:BNTC) - Seeking Alpha
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $19.50 Average Target Price from Analysts - MarketBeat
Oppenheimer Begins Coverage on Benitec Biopharma (NASDAQ:BNTC) - MarketBeat
JMP Securities Increases Benitec Biopharma (NASDAQ:BNTC) Price Target to $18.00 - Defense World
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update - MarketBeat
Benitec Biopharma Reports Promising Results for BB-301 Trial - TipRanks
Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial - CGTLive™
Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Gene Silencing Market to Expand with Significant CAGR by 2034 |Alnylam Pharmaceuticals, Benitec Biopharma, Arrowhead Pha – IndiaPolitics.com - IndiaPolitics.com
JMP Securities Raises Benitec Biopharma (NASDAQ:BNTC) Price Target to $18.00 - MarketBeat
Piper Sandler maintains Overweight rating on Benitec BioPharma stock By Investing.com - Investing.com UK
Leerink reiterates Benitec BioPharma at Outperform following new BB-301 data - Investing.com Canada
Benitec Biopharma Announces Updated Investor Webcast Information - GlobeNewswire
Global Antisense & RNAi Therapeutics Market Growth in Future - openPR
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase - The Bakersfield Californian
Benitec Biopharma Reports Positive Data from Two Subjects - GlobeNewswire
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society - StockTitan
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
RNAi Therapeutics Market Focusing on Trends and Innovations - openPR
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Benitec Biopharma's BB-301: Potential In OPMD, But Still Too Early Stages (NASDAQ:BNTC) - Seeking Alpha
Benitec Biopharma Inc. Reports on Recent Stockholder Activity - MarketBeat
Benitec Biopharma issues shares after warrant exercises By Investing.com - Investing.com South Africa
Benitec Biopharma issues shares after warrant exercises - Investing.com India
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
When the Price of (BNTC) Talks, People Listen - Stock Traders Daily
Fresh Study Reveals the Duchenne Muscular Dystrophy Market Insights, Demand, and Forecast to 2033 - WhaTech
Benitec Biopharma Stock (BNTC) Surges on Potentially Groundbreaking OPMD Treatment - Nasdaq
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth - Simply Wall St
Benitec Biopharma stock soars to 52-week high of $10.9 By Investing.com - Investing.com South Africa
Nantahala Capital Management LLC Buys New Shares in Benitec Biopharma Inc. (NASDAQ:BNTC) - Defense World
Benitec Biopharma stock soars to 52-week high of $10.9 - Investing.com India
Nantahala Capital Management LLC Buys Shares of 841,395 Benitec Biopharma Inc. (NASDAQ:BNTC) - MarketBeat
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc - Yahoo Finance
JMP Securities Reiterates Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC) - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Benitec Biopharma (NASDAQ:BNTC) - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Above 50 Day Moving Average of $8.85 - MarketBeat
Wall Street SWOT: Benitec Biopharma stock shows promise with OPMD treatment - Investing.com
Wall Street SWOT: Benitec Biopharma stock shows promise with OPMD treatment By Investing.com - Investing.com South Africa
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - The Bakersfield Californian
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):